Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study

@article{Bergamasco2000AlphadihydroergocryptineIT,
  title={Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study},
  author={Bruno Bergamasco and Lodovico Frattola and Alberto Muratorio and Federico Piccoli and Federico Mailland and Lucilla Parnetti},
  journal={Acta Neurologica Scandinavica},
  year={2000},
  volume={101}
}
Introduction– A multicentre, randomized, double‐blind, placebo‐controlled, parallel group study was carried out in 123 patients suffering from never treated (de novo) idiopathic Parkinson's disease (PD). The aim of the study was to confirm the efficiency and safety of α‐dihydroergocryptine (α‐DHEC) given as monotherapy in the symptomatic treatment of PD. The total score of the Unified Parkinson's Disease Rating Scale (UPDRS) was identified as the efficacy target variable. Patients and methods… 
Alpha-Dihydroergocryptine vs. Pramipexole as Adjunct Symptomatic Treatment of Idiopathic Parkinson’s
TLDR
DHEC and PRAM proved to be effective and safe as adjunct therapy to levodopa in idiopathic PD and have significantly improved the motor function of patients, according to the research result.
Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of changes in DAT binding with [123I]IPT SPECT
TLDR
The results of this pilot study suggest that as compared to levodopa monotherapy DEC may have beneficial effects on decline of dopamine transporter binding similar to those recently described for pramipexole.
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists
TLDR
Clinical studies on the use of dihydroergocriptine, an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease indicate that DHEC is an efficacious remedy for parkinsonian signs and symptoms.
Treatment of restless legs syndrome with the dopamine agonist alpha‐dihydroergocryptine
TLDR
An open pilot study with the dopamine agonist α‐dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome, suggesting a role for DHEC in the treatment of RLS.
Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
Influence of the Dopamine Agonist &agr;-Dihydroergocryptine on the Pharmacokinetics of Levodopa in Patients with Parkinson's Disease
TLDR
The magnitude of the interaction does not suggest changing the current clinical practice of up-titrating DHEC and subsequently adapting L-Dopa to the individual needs of patients, and the effect was small but statistically significant for the area under the plasma concentration–time curve.
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
TLDR
The STRIDEPD study failed to prove the benefit of continuous dopaminergic stimulation with triple therapy in a clinical setting, and clear evidence has been presented indicating homocysteine as a risk factor for vascular diseases, cognitive impairment, and dementia.
Dopamine Agonists in Parkinson Disease : Special Focus on Pramipexole
TLDR
In addition to abating the core symptoms of PD and delaying the onset of motor complications, the dopamine agonist pramipexole has been shown to ameliorate tremor and depressive symptoms in clinical practice.
Dopamine agonist therapy in early Parkinson's disease.
TLDR
This meta-analysis confirms that motor complications are reduced with dopamine agonists compared to levodopa, but also establishes that other important side-effects are increased and symptom control is poorer with agonists.
Synergistic effect of α-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture
TLDR
The novel finding that the combination of a dopamine (DA) agonist, α-dihydroergocryptine (DHEC), with L-dopa or DA exerts a synergistic stimulatory effect on dopaminergic neurons in primary culture, while each substance alone had no or less effect is described.
...
1
2
3
4
...

References

SHOWING 1-10 OF 33 REFERENCES
Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
TLDR
Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in Terms of the incidence and severity of adverse events.
Cabergoline in the treatment of early parkinson's disease
TLDR
The results of this study indicate that cabergoline treatment for up to 1 year is only marginally less effective than levodopa in the proportion of patients who can be treated in monotherapy.
Long‐term bromocriptine treatment of de novo patients with Parkinson's disease. A seven‐year follow‐up
TLDR
The number of fluctuations in disability was smaller in the patients whose symptomatology was controlled by bromocriptine monotherapy than in those requiring levodopa, either alone or combined with bromOCriptine.
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
TLDR
Deprenyl but not tocopherol delays the onset of disability associated with early, otherwise untreated Parkinson's disease and the action of deprenyl that accounts for its beneficial effects remains unclear.
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
TLDR
Levodopa-carbidopa in low dosage adequately controlled symptoms in most patients and delayed the appearance of dyskinesia and end of dose failure for about two years longer than conventional doses.
Bromocriptine: long-term low-dose therapy in Parkinson's disease.
TLDR
Bromocriptine did not induce dyskinesia, the wearing-off response, or the on-off phenomenon in de novo subjects and was used as a first choice drug in these parkinsonian patients.
Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease
  • N. Ogawa
  • Medicine, Psychology
    Neurology
  • 1998
Recent efforts in treatment of Parkinson's disease (PD) have focused on the development of agents or strategies that suppress or delay disease progression and levodopa-induced adverse reactions. In
Does levodopa therapy delay death in Parkinson's disease? A review of the evidence
  • C. Clarke
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 1995
TLDR
It is concluded that the decrease in crude mortality rate in the early 1970s in several western countries was mirrored by a decrease in observed to expected mortality rates in cohort studies over the same period, compatible with the hypothesis that levodopa delayed the death of a cohort of frail elderly parkinsonian patients who succumbed ∼5 years later, leading to an apparent “catch‐up” increment in national mortality data.
The role of dopamine agonists in early Parkinson's disease
  • R. Watts
  • Biology, Psychology
    Neurology
  • 1997
TLDR
The traditional role of dopamine agonist monotherapy is reviewed and emerging strategies for the treatment of PD are focused on, including early monotherapy with dopamine agonists and early combination therapy with Parkinson's disease patients and levodopa.
...
1
2
3
4
...